3Pritzker KH. Cancer biomarkers : easier said than done. Clin Chem, 2002,48: 1147- 1150.
4Fleisher M, Dnistrian AM, Sturgeon CM, et al. Practice guidelines and recommendations for use tumor markers in the clinic. Washington DC: AACC Press,2002.20-25
6Lakhani SR, Ashworth A. Microarray and histo-pathological analysis of tumours:the future and the past? Nature Rev Cancer, 2001,1:151-157.
7Yu H, Diamandis EP, Levesque M, et al. Prostate specific antigen in breast cancer benign breast disease and normal breast tissue. Breast Cancer Res Treat, 1996,40:171- 178.
8Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer, 2003,3:267-275.
9Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer, 2002, 2:210-219.
10Sun X, Hung K, Wu L, et al. Detection of tumor mutations in the presence of excess amounts of normal DNA. Nat Biotechol, 2002,20:186-189.
1Sun Z H,Fu X L,Zhang L,et al. A protein chip system for parallel analysis of muhi-tumor markers and it s application in cancer detection [J]. Anticancer Res ,2004,24(2C) : 1159 - 66.
2Lueking A,Cahill D J,Mullner S. Protein biochips:A new and versatile platform technology for molecular medicine [J]. Drug Discov Today,2005, 10( 11 ) :789 - 94.
3Elrick M M, Walgren J L, Mitchell M D. Proteomics:recent applications and Newtechnologies [ J ]. Basic Clin Pharmacol Toxicol, 2006,98(5) :432 -41.
4Graham D R, Elliott S T, Van Eyk J E. Broad-based proteomic strategies:a practical guide to proteomics and functional screening [ J ]. J Physiol,2005,563 ( Pt 1 ) :1 - 9.
